Professor Allen Chan and his research team completed a prospective clinical trial on using plasma Epstein-Barr virus (EBV) DNA for the screening of early asymptomatic nasopharyngeal carcinoma (NPC). They demonstrated that NPC screening can significantly detect cancer patients at earlier stages and improve their treatment outcomes. The team is proceeding with the second phase of the study and are screening all enrolled subjects at 4 years after the initial screening. This follow-up study can address the optimal interval for NPC screening and if those non-cancer individuals with detectable plasma EBV DNA would have an increased risk of developing NPC in the future. Professor Chan was bestowed with the Inaugural Lo Ying Shek Chi Wai Foundation Meritorious Research Award in 2019.
### Publications

**A. Journal Papers**


